Biotech

Gilead and Kites exhibit booth at ASH 2025
Biotech

ASH: Anito-cel strengthens potential as Kite preps for launch

The Arcellx-partnered therapy achieved a 96% overall response rate at the 15.9 month mark, with 74% of patients’ cancer disappearing completely.
Darren Incorvaia Dec 7, 2025 11:52am
Stars twinkling in the night sky

Star antibody sparkles in preview of potential ph. 3 success

Dec 7, 2025 9:40am
Carl Sailer on AI market trends and strategic planning in biotech

Carl Sailer on AI, market trends, and strategic planning in biotech

Oct 28, 2024 8:00pm
big wave over ship in storm

mRNA coalition demands stable FDA leadership amid vaccine changes

Dec 5, 2025 1:36pm
Guidehouses Karla Anderson shares top tips for successful biotech commercialization

Guidehouse’s Karla Anderson shares top tips for successful biotech commercialization

Oct 28, 2024 8:00am
DNA strand

Encoded deciphers pivotal path with phase 1/2 gene therapy data

Dec 5, 2025 12:45pm